News &amp; Updates

Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) rarely results in severe drug-induced liver injury among adults with cystic fibrosis, as shown in a study presented at AASLD 2023. Moreover, serum markers of fibrosis have increased but remain within normal range.

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

Is dexmedetomidine safer than usual care for critically ill older adults?

The incidence of adverse events among critically ill older patients is similar between those receiving dexmedetomidine and those receiving usual care, a study has shown.

Is dexmedetomidine safer than usual care for critically ill older adults?

Bulevirtide-PegIFNα combo yields benefits for CHD patients

A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Adjuvant alectinib boosts DFS in early stage, resected ALK+ NSCLC

Adjuvant targeted treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly improved disease-free survival (DFS) at 2 years compared with platinum-based chemotherapy in patients with early stage, completely resected ALK-positive non-small cell lung cancer (ALK+ NSCLC) in the primary analysis of the phase III ALINA trial.

Adjuvant alectinib boosts DFS in early stage, resected ALK+ NSCLC

Alpha blockers tied to less favourable cardiovascular profile than 5-ARIs in BPH

In the treatment of men with benign prostatic hyperplasia (BPH), alpha blockers appear to be associated with worse cardiovascular outcomes compared with 5-alpha reductase inhibitors (5-ARIs), as shown in a study.

Alpha blockers tied to less favourable cardiovascular profile than 5-ARIs in BPH

Semaglutide reduces CV risk in overweight/obese patients without T2D

Treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) among overweight/obese patients with pre-existing cardiovascular (CV) disease but without type 2 diabetes (T2D), according to the SELECT trial presented at AHA 2023.

Semaglutide reduces CV risk in overweight/obese patients without T2D

Naltrexone, acamprosate favoured in meta-analysis of alcohol use disorder medications

Oral naltrexone and acamprosate are associated with improved outcomes in individuals with alcohol use disorder and are supported as first-line pharmacotherapies in a meta-analysis.

Naltrexone, acamprosate favoured in meta-analysis of alcohol use disorder medications

Remdesivir, favipiravir may not be heart-friendly

20 Nov 2023 by

Remdesivir and favipiravir does not appear to be heart-friendly in patients with COVID-19, according to a study presented at APSR 2023.

Remdesivir, favipiravir may not be heart-friendly

20 Nov 2023

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 by

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023 by

Use of antihypertensive medications does not appear to reduce the risk of all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF), reports a study presented at AHA 2023. However, treatment with antihypertensives can lower the risk of adverse cardiovascular (CV) outcomes regardless of the patient’s hypertension status.

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients